Vandana Singh - Benzinga

SPY757.84+0.28%QQQ690.99+0.07%BTC/USD77,184.90−1.33%DIA521.73+0.89%GLD362.57+1.91%TLT82.12+0.34%

Premium Services

Articles by Vandana Singh

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott reports positive trial results for its Amulet 360 LAA occluder and SonicForce coronary IVL system at a conference.

Tempus AI Says It Is Uniquely Positioned

Tempus AI Says It Is Uniquely Positioned

Tempus AI stock rises after beating Q3 earnings estimates and securing $192.5 million in data deals with Bristol Myers Squibb and Pathos.

Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic

Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic

IDEXX tops Q3 estimates and lifts 2026 guidance as rising test intensity and global instrument sales offset softer U.S. veterinary clinic traffic.

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

FDA grants Priority Review to uniQure for its Huntington's gene therapy, setting a PDUFA target date of May 1, 2027.

Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease Immunotherapy

Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease Immunotherapy

Inovio stock surges after FDA accelerated approval of Voceryq, an immunotherapy reducing surgeries for adults with recurrent respiratory papillomatosis.

Why Is Teva Stock Trading Lower on Monday?

Why Is Teva Stock Trading Lower on Monday?

Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.

FDA Setback Clouds Timeline For Bright Minds Biosciences' Pediatric Epilepsy Trials

FDA Setback Clouds Timeline For Bright Minds Biosciences' Pediatric Epilepsy Trials

The FDA places a partial clinical hold on Bright Minds Biosciences' Phase 2 epilepsy study after mouse toxicity and pediatric data concerns.

Merck One of Top Large-Cap Biopharma Picks-Analyst

Merck One of Top Large-Cap Biopharma Picks-Analyst

Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.

AbbVie Raises 2026 Outlook, Boosts Dividend

AbbVie Raises 2026 Outlook, Boosts Dividend

AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.

Eli Lilly 'Deserves' Stock Upside: Analyst

Eli Lilly 'Deserves' Stock Upside: Analyst

Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.

Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps

Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps

Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.

Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

Sanofi beats Q3 earnings consensus on Dupixent growth, raises 2026 guidance, and outlines long-term plans to handle upcoming patent expirations.

AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth

AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth

AstraZeneca beats Q3 2026 targets as oncology offsets Farxiga losses, backed by a $2 billion pipeline restructuring push.

Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation

Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.

Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact

Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact

Bristol-Myers beats Q3 2026 estimates with $13.07B in revenue and raises full-year sales guidance driven by newer drug growth.

Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027

Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027

Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.

Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.

Why Is Baxter Stock Trading Lower on Thursday?

Why Is Baxter Stock Trading Lower on Thursday?

Baxter tops Q3 consensus with 58 cents EPS and $2.976 billion in sales, lifting fiscal 2026 profit and revenue guidance above Wall Street forecasts.

Consumer Healthcare Giant Haleon Plunges to 52-Week Low

Haleon shares hit a 52-week low as the company trimmed full-year sales targets to 2.5% amid China import halts and Brazil adjustments.

Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion

Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion

Eli Lilly tops Q3 forecasts on surging Mounjaro sales, raises 2026 revenue outlook to $92 billion, and hits new 52-week highs despite an EPS forecast trim.